Methylprednisolone Dosing for Patients with Hypertension due to ADPKD and Multiple Sclerosis

Special Considerations for ADPKD with Hypertension

The American Society of Nephrology recommends that hypertension management is critical in ADPKD patients, as it's one of the most common complications and can worsen with corticosteroid treatment, with renin-angiotensin system inhibitors (ACEi or ARB) as the recommended first-line treatment for hypertension in ADPKD patients 1, 2
For ADPKD patients aged 18-49 years with CKD G1-G2, the National Kidney Foundation suggests a target blood pressure of ≤110/75 mmHg if tolerated, with more intensive blood pressure monitoring required during corticosteroid treatment due to potential fluid retention and blood pressure elevation 1, 4
The European Renal Association recommends that for ADPKD patients aged ≥50 years and/or with CKD G3-G5, target mean systolic blood pressure should be <120 mmHg if tolerated, with careful monitoring of blood pressure and renal function 1
The International Society of Nephrology advises that more intensive blood pressure monitoring is required during corticosteroid treatment due to potential fluid retention and blood pressure elevation, with consideration of temporary addition of calcium channel blockers or diuretics if blood pressure increases during treatment 5, 6

The Kidney International guideline recommends evaluating current blood pressure control and kidney function (eGFR) before starting methylprednisolone treatment, with intensification of antihypertensive therapy before starting corticosteroids if blood pressure is not at target 1, 2
The National Multiple Sclerosis Society suggests that for moderate to severe MS exacerbations, methylprednisolone 1000 mg IV daily for 3-5 days can be administered, with alternative oral methylprednisolone equivalent (1250 mg daily for 3-5 days) if IV administration is not feasible, and consideration of lower dose of 625 mg daily for 3 days for mild exacerbations 7
The American College of Nephrology recommends monitoring blood pressure daily during corticosteroid treatment, with consideration of temporary addition of calcium channel blockers or diuretics if blood pressure increases during treatment, and checking serum creatinine before treatment and 3-5 days after completion 1, 6

The European Society of Hypertension advises that corticosteroids can cause significant fluid retention, which may exacerbate hypertension and increase kidney cyst volume in ADPKD patients, with careful monitoring of blood pressure and renal function 1
The International Society of Nephrology recommends being cautious with concomitant medications that may affect renal function or blood pressure control, with consideration of alternative immunomodulatory therapies after consultation with both nephrology and neurology 8
The National Kidney Foundation suggests that although high-dose pulse therapy for MS typically doesn't require tapering, consideration of a brief taper if treatment exceeds 5 days to prevent adrenal suppression is necessary, with schedule close follow-up within 1-2 weeks after treatment to assess response and monitor for complications 7, 1